Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)
Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $23.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "Remain OW rated on BCRX shares after a solid Q424 Orladeyo print, reporting $124.2M versus the $123.5M preliminary revenue pre-released last month. Given management’s expectations around IRA benefit this year, FY25 Orladeyo revenue guidance was raised $17.5M at the midpoint. Beyond this, the path to probability remains intact even with pipeline investment in BCX17725 (Netherton syndrome) and avoralstat (DME) clinical development. Bottom line - we remain encouraged by this name’s durable commercial franchise and growing pipeline of innovative therapies. As noted, with this name having little to no take-out premium (currently trading at ~3X 2025 revenue guidance), we like the valuation and clinical setup. Remain buyers."
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $9.21 yesterday.